Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Are PPIs created equal?

Executive Summary

Consumer Reports Best Buy Drugs recommends Procter & Gamble's Prilosec OTC, primarily due to cost advantages with the OTC proton pump inhibitor. The latest report compares Prilosec and Prilosec OTC, AstraZeneca's Nexium, TAP's Prevacid, Schering-Plough/Santarus' combination Zegerid, Wyeth's Protonix and Johnson & Johnson/Eisai's Aciphex and concludes that the drugs "are roughly equal in effectiveness and safety, but differ in cost." The report also suggests that claims by AstraZeneca that Nexium is the best drug for people with GERD and esophagitis are "marginal at best." AstraZeneca responds that Nexium controls stomach acid production better than any brand PPI and that the blockbuster PPI is clinically proven to heal damage to the esophagus, which Prilosec OTC has not demonstrated...

You may also be interested in...

QUOTED. 25 February 2021. Adam Saltman.

A recent FDA action plan on artificial intelligence and machine learning (AI/ML) medical software could encourage more to jump in, said Eko Chief Medical Officer Adam Saltman.

Daiichi's Novel EZH Candidate Moves Ahead With New Consortium Trial

Japanese major links with new partners in European consortium to progress first-in-class molecule for multiple hematological malignancies.

J&J's COVID-19 Vaccine May Face Efficacy Comparison Questions At US FDA Panel Review

Efficacy against moderate to severe/critical COVID-19 was 66%-67%, well above the FDA’s stated 50% efficacy threshold for an EUA but far short of the 94%+ efficacy rates posted by the Pfizer and Moderna vaccines against symptomatic disease; agency says efficacy against specific variants cannot be evaluated at this time because sequencing data are incomplete.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts